Press coverage about TRACON Pharmaceuticals (NASDAQ:TCON) has trended positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. TRACON Pharmaceuticals earned a news impact score of 0.31 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the immediate future.

A number of research analysts recently issued reports on the company. Stifel Nicolaus decreased their price objective on TRACON Pharmaceuticals from $14.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, June 13th. Zacks Investment Research downgraded TRACON Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. TRACON Pharmaceuticals has a consensus rating of “Hold” and an average target price of $8.88.

TRACON Pharmaceuticals (NASDAQ:TCON) traded up 2.22% on Monday, hitting $2.30. The company had a trading volume of 2,942 shares. The company’s market capitalization is $38.20 million. TRACON Pharmaceuticals has a one year low of $2.00 and a one year high of $7.30. The stock’s 50-day moving average price is $2.65 and its 200 day moving average price is $3.88.

TRACON Pharmaceuticals (NASDAQ:TCON) last issued its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.03. TRACON Pharmaceuticals had a negative return on equity of 126.77% and a negative net margin of 964.36%. The business had revenue of $0.63 million during the quarter, compared to analyst estimates of $0.92 million. On average, analysts expect that TRACON Pharmaceuticals will post ($2.00) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/tracon-pharmaceuticals-tcon-receives-media-impact-rating-of-0-31/1445173.html.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).

Insider Buying and Selling by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

Receive News & Ratings for TRACON Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.